Progenitor

Progenitor Life Sciences is a biotechnology company focused on developing "off-the-shelf" cellular immunotherapies using its proprietary induced pluripotent stem cell (iPSC) platform. The company's technology aims to create immune-evasive, ready-to-use CAR-T and CAR-NK cells that can be administered to patients without the need for personalized manufacturing. By leveraging genetic engineering and stem cell biology, Progenitor seeks to overcome the limitations of current autologous therapies, such as high costs and long lead times. Their pipeline primarily targets various cancers, utilizing a scalable manufacturing approach to provide accessible cell-based treatments.